216 related articles for article (PubMed ID: 12893330)
21. Bipolar plasmakinetic transurethral resection of prostate in 132 consecutive patients with large gland: three-year follow-up results.
Zhu G; Xie C; Wang X; Tang X
Urology; 2012 Feb; 79(2):397-402. PubMed ID: 22035765
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of short term clinical effects and presumptive mechanism of botulinum toxin type A as a treatment modality of benign prostatic hyperplasia.
Park DS; Cho TW; Lee YK; Lee YT; Hong YK; Jang WK
Yonsei Med J; 2006 Oct; 47(5):706-14. PubMed ID: 17066515
[TBL] [Abstract][Full Text] [Related]
23. The application of botulinum toxin in the prostate.
Chuang YC; Chancellor MB
J Urol; 2006 Dec; 176(6 Pt 1):2375-82. PubMed ID: 17085104
[TBL] [Abstract][Full Text] [Related]
24. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group.
Roehrborn CG; McConnell JD; Lieber M; Kaplan S; Geller J; Malek GH; Castellanos R; Coffield S; Saltzman B; Resnick M; Cook TJ; Waldstreicher J
Urology; 1999 Mar; 53(3):473-80. PubMed ID: 10096369
[TBL] [Abstract][Full Text] [Related]
25. Effect of onabotulinum toxin type a intraprostatic injection on the outcome of Benign Prostatic Hyperplasia patients refractory to medical therapy: A 2-year follow-up study.
Rodrigues de Carvalho TG; Pinto R; Cruz F; Silva J
Arch Esp Urol; 2016 Dec; 69(10):719-726. PubMed ID: 28042794
[TBL] [Abstract][Full Text] [Related]
26. Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients.
Gallien P; Reymann JM; Amarenco G; Nicolas B; de Sèze M; Bellissant E
J Neurol Neurosurg Psychiatry; 2005 Dec; 76(12):1670-6. PubMed ID: 16291892
[TBL] [Abstract][Full Text] [Related]
27. Change in International Prostate Symptom Score, prostrate-specific antigen and prostate volume in patients with benign prostatic hyperplasia followed longitudinally.
Tsukamoto T; Masumori N; Rahman M; Crane MM
Int J Urol; 2007 Apr; 14(4):321-4; discussion 325. PubMed ID: 17470162
[TBL] [Abstract][Full Text] [Related]
28. Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction.
Phelan MW; Franks M; Somogyi GT; Yokoyama T; Fraser MO; Lavelle JP; Yoshimura N; Chancellor MB
J Urol; 2001 Apr; 165(4):1107-10. PubMed ID: 11257648
[TBL] [Abstract][Full Text] [Related]
29. Tadalafil Improves Symptoms, Erectile Function and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (KYU-PRO Study).
Takahashi R; Miyazato M; Nishii H; Sumino Y; Takayama K; Onzuka M; Oshiro T; Saito S; Fujimoto N; Mimata H; Eto M
Low Urin Tract Symptoms; 2018 Jan; 10(1):76-83. PubMed ID: 29341501
[TBL] [Abstract][Full Text] [Related]
30. A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia.
Marberger M; Chartier-Kastler E; Egerdie B; Lee KS; Grosse J; Bugarin D; Zhou J; Patel A; Haag-Molkenteller C
Eur Urol; 2013 Mar; 63(3):496-503. PubMed ID: 23098762
[TBL] [Abstract][Full Text] [Related]
31. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Morrill B; Montorsi F;
J Urol; 2008 Feb; 179(2):616-21; discussion 621. PubMed ID: 18082216
[TBL] [Abstract][Full Text] [Related]
32. Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomized clinical trial.
Crawford ED; Hirst K; Kusek JW; Donnell RF; Kaplan SA; McVary KT; Mynderse LA; Roehrborn CG; Smith CP; Bruskewitz R
J Urol; 2011 Sep; 186(3):965-70. PubMed ID: 21791356
[TBL] [Abstract][Full Text] [Related]
33. Transurethral microwave treatment for benign prostatic hypertrophy: a randomised controlled clinical trial.
Bdesha AS; Bunce CJ; Kelleher JP; Snell ME; Vukusic J; Witherow RO
BMJ; 1993 May; 306(6888):1293-6. PubMed ID: 7686065
[TBL] [Abstract][Full Text] [Related]
34. Treatment of Benign Prostatic Hyperplasia by Ultrasound-Guided Botulinum Toxin Type A Injection.
Ding XD; Chen HX; Xiao HQ; Wang W; Ding ZG; Zhang GB; Fu DG
Cell Biochem Biophys; 2015 Nov; 73(2):357-359. PubMed ID: 27352323
[TBL] [Abstract][Full Text] [Related]
35. Serial prostate-specific antigen measurements in men with clinically benign prostatic hyperplasia during a 12-month placebo-controlled study with terazosin. HYCAT Investigator Group. Hytrin Community Assessment Trial.
Roehrborn CG; Oesterling JE; Olson PJ; Padley RJ
Urology; 1997 Oct; 50(4):556-61. PubMed ID: 9338731
[TBL] [Abstract][Full Text] [Related]
36. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.
Gormley GJ; Stoner E; Bruskewitz RC; Imperato-McGinley J; Walsh PC; McConnell JD; Andriole GL; Geller J; Bracken BR; Tenover JS
N Engl J Med; 1992 Oct; 327(17):1185-91. PubMed ID: 1383816
[TBL] [Abstract][Full Text] [Related]
37. A dose-response study of the effect of flutamide on benign prostatic hyperplasia: results of a multicenter study.
Narayan P; Trachtenberg J; Lepor H; Debruyne FM; Tewari A; Stone N; Das S; Jimenez-Cruz JF; Shearer R; Klimberg I; Schellhammer PF; Costello AJ
Urology; 1996 Apr; 47(4):497-504. PubMed ID: 8638357
[TBL] [Abstract][Full Text] [Related]
38. A multicenter, double-blind, placebo-controlled trial of the efficacy of prazosin in the treatment of dysuria associated with benign prostatic hypertrophy.
Le Duc A; Cariou G; Baron C; Cukier J; Quentel P; Faure G; Rambeaud JJ; Navratil H; Costa P; Richaud JJ
Urol Int; 1990; 45 Suppl 1():56-62. PubMed ID: 1690483
[TBL] [Abstract][Full Text] [Related]
39. Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia.
Schulman CC; Lock TM; Buzelin JM; Boeminghaus F; Stephenson TP; Talja M;
J Urol; 2001 Oct; 166(4):1358-63. PubMed ID: 11547074
[TBL] [Abstract][Full Text] [Related]
40. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
